Yi-Long Wu, Shun Lu, Ying Cheng, Qing Zhou, H. Tu, Qing Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, S. Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, Anwen Liu, Xu‐Chao Zhang, Hui Li, Rong-rong Chen, Dong‐Mei Lin, Congying Xie, Zheng‐Fei Zhu, Hui-Ying Liang, Yong Song, Xiaorong Dong, Ming‐Fang Zhao, Gui-Bin Qiao, J. Cui, Ziming Li, Zhijie Wang, Xiao-Yuan Chen, N. Yang, G. Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, J. Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Q-T Yu, Li‐Feng Wang, Hai-bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui-juan Wang, Fang Wu, Wenzhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Li Zhang, Fan Yang, Qun Wang, Dongsheng Yue, Jianying Zhou, Peng Shen, Jia‐Tao Zhang, XiaoLan Yan, Meijuan Huang, Wei Feng, Li Li
{"title":"Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention","authors":"Yi-Long Wu, Shun Lu, Ying Cheng, Qing Zhou, H. Tu, Qing Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, S. Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, Anwen Liu, Xu‐Chao Zhang, Hui Li, Rong-rong Chen, Dong‐Mei Lin, Congying Xie, Zheng‐Fei Zhu, Hui-Ying Liang, Yong Song, Xiaorong Dong, Ming‐Fang Zhao, Gui-Bin Qiao, J. Cui, Ziming Li, Zhijie Wang, Xiao-Yuan Chen, N. Yang, G. Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, J. Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Q-T Yu, Li‐Feng Wang, Hai-bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui-juan Wang, Fang Wu, Wenzhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Li Zhang, Fan Yang, Qun Wang, Dongsheng Yue, Jianying Zhou, Peng Shen, Jia‐Tao Zhang, XiaoLan Yan, Meijuan Huang, Wei Feng, Li Li","doi":"10.1002/med4.44","DOIUrl":null,"url":null,"abstract":"The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challenge for diagnosis and therapeutic targeting. In the never‐smokers/low smokers category with mutations such as EGFR and HER2, the efficacy of immune checkpoint inhibitors (ICIs) remains suboptimal, attributed to lower PD‐L1 expression and tumor mutation burden (TMB). However, heavy smokers, often with mutations like KRAS, may derive benefits from ICIs, as supported by trials like CheckMate‐057. With the complex landscape of these drivers and their clinical implications, the summit culminated in six pivotal consensus points, aiming to guide future research and clinical decisions. Despite the advancements, the detection, interpretation, and therapeutic strategies involving these drivers necessitate further exploration and standardization.","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine Advances","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1002/med4.44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challenge for diagnosis and therapeutic targeting. In the never‐smokers/low smokers category with mutations such as EGFR and HER2, the efficacy of immune checkpoint inhibitors (ICIs) remains suboptimal, attributed to lower PD‐L1 expression and tumor mutation burden (TMB). However, heavy smokers, often with mutations like KRAS, may derive benefits from ICIs, as supported by trials like CheckMate‐057. With the complex landscape of these drivers and their clinical implications, the summit culminated in six pivotal consensus points, aiming to guide future research and clinical decisions. Despite the advancements, the detection, interpretation, and therapeutic strategies involving these drivers necessitate further exploration and standardization.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
